Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA.
Virology. 2010 Sep 15;405(1):20-5. doi: 10.1016/j.virol.2010.06.022. Epub 2010 Jul 3.
Merkel cell polyomavirus (MCV) has been implicated as a causative agent in Merkel cell carcinoma. Robust polyclonal antibody responses against MCV have been documented in human subjects, but monoclonal antibodies (mAbs) specific for the VP1 capsid protein have not yet been characterized. We generated 12 mAbs capable of binding recombinant MCV virus-like particles. The use of a short immunogenic priming schedule was important for production of the mAbs. Ten of the 12 mAbs were highly effective for immunofluorescent staining of cells expressing capsid proteins. An overlapping set of 10 mAbs were able to neutralize the infectivity of MCV-based reporter vectors, with 50% effective doses in the low picomolar range. Three mAbs interfered with the binding of MCV virus-like particles to cells. This panel of anti-capsid antibodies should provide a useful set of tools for the study of MCV.
默克尔细胞多瘤病毒(MCV)已被认为是默克尔细胞癌的致病因子。在人体中已经记录到针对 MCV 的强多克隆抗体反应,但尚未对 VP1 衣壳蛋白的单克隆抗体(mAbs)进行特征描述。我们生成了 12 种能够结合重组 MCV 病毒样颗粒的 mAbs。使用短的免疫原性启动时间表对于 mAbs 的生产非常重要。12 种 mAbs 中的 10 种对表达衣壳蛋白的细胞的免疫荧光染色非常有效。一组重叠的 10 种 mAbs 能够中和基于 MCV 的报告载体的感染性,半数有效剂量在低皮摩尔范围内。三种 mAbs 干扰 MCV 病毒样颗粒与细胞的结合。该衣壳抗体小组应该为 MCV 的研究提供一组有用的工具。